Drug immunotargeting for carcinomas: A reality at last?
- 1 October 1994
- journal article
- review article
- Published by Elsevier in Annals of Oncology
- Vol. 5 (8) , 703-708
- https://doi.org/10.1093/oxfordjournals.annonc.a058974
Abstract
A. M. Casazza, P. A. Trail, K. E. Hellström; Drug immunotargeting for carcinomas: A reality at last?, Annals of Oncology, Volume 5, Issue 8, 1 October 1994, PaKeywords
This publication has 9 references indexed in Scilit:
- Anti-tumor antibody BR96 blocks cell migration and binds to a lysosomal membrane glycoprotein on cell surface microspikes and ruffled membranes.The Journal of cell biology, 1994
- (6-Maleimidocaproyl)hydrazone of doxorubicin. A new derivative for the preparation of immunoconjugates of doxorubicinBioconjugate Chemistry, 1993
- Cure of Xenografted Human Carcinomas by BR96-Doxorubicin ImmunoconjugatesScience, 1993
- Antibody Conjugates for the Treatment of CancerImmunological Reviews, 1992
- Phase I/II study of monoclonal antibody against Lewis Y hapten in relapsed small-cell lung cancerAnnals of Oncology, 1992
- Preparation and characterization of a water soluble dextran immunoconjugate of doxorubicin and the monoclonal antibody (ABL 364)Journal of Controlled Release, 1992
- New hydrazone derivatives of Adriamycin and their immunoconjugates - a correlation between acid stability and cytotoxicityBioconjugate Chemistry, 1991
- Homologous recombination in hybridoma cells: heavy chain chimeric antibody produced by gene targeting.Proceedings of the National Academy of Sciences, 1989
- Characterization of the Human Tumor and Normal Tissue Reactivity of the KS1/4 Monoclonal AntibodyHybridoma, 1988